Prescription medicine
Donepezil and memantine Brand names: Namzaric
Donepezil and memantine (Namzaric) is a prescription medicine with an FDA approval on record since 2014. FDA's NDC Directory lists it from 5 generic labelers, and pharmacies paid $8.44 per unit (Memantine-donepezil ER 28-10 mg) in the October 7, 2026 NADAC survey; its other strengths are brand-only, $19.80 per Namzaric 28 mg-10 mg capsule.
- Generic listed
- A presentation discontinued
Check it at the source: the donepezil and memantine FDA label on DailyMed (effective December 17, 2024, Amneal Pharmaceuticals NY LLC); the NDA 206439 record on Drugs@FDA; every donepezil and memantine label on DailyMed.
Highlights of the record
FDA label of December 17, 2024; NDC Directory, Drugs@FDA and Orange Book, October 8, 2026; NADAC October 7, 2026
Used for
From the label: indications and usageMemantine and donepezil hydrochlorides extended-release capsules are indicated for the treatment of moderate to severe dementia of the Alzheimer’s type in patients stabilized on 10 mg of donepezil hydrochloride once daily.
Forms and strengths
- 7 mg / 10 mg
- 14 mg / 10 mg
- 21 mg / 10 mg
- 28 mg / 10 mg
Extended-release capsule; capsule.
On the market
- Earliest approval on file
- December 23, 2014 Namzaric, Abbvie; Drugs@FDA’s file, where older or withdrawn approvals can be missing
- Generic approvals
- 4 first January 27, 2017; 4 with a marketed status in Drugs@FDA
- Labelers listed (NDC)
- 6 of which 5 under generic applications, 1 under brand applications, repackagers included
- Last listed patent
- December 5, 2029 Namzaric capsules; not a generic launch date
Supply and safety
- Pharmacy cost (NADAC)
- $8.44 per unit Memantine-donepezil ER 28-10 mg
- Shortage (FDA)
- None current 2 past records
- Recalls by its makers (FDA)
- 1 since 2021 0 Class I among all firms' recalls; latest March 15, 2021
- FAERS reports
- 608 through July 30, 2026
What is donepezil and memantine used for?
From the label: indications and usageMemantine and donepezil hydrochlorides extended-release capsules are indicated for the treatment of moderate to severe dementia of the Alzheimer’s type in patients stabilized on 10 mg of donepezil hydrochloride once daily. Memantine and donepezil hydrochlorides extended-release capsules are a combination of memantine hydrochloride, an NMDA receptor antagonist, and donepezil hydrochloride, an acetylcholinesterase inhibitor, indicated for the treatment of moderate to severe dementia of the Alzheimer’s type in patients stabilized on 10 mg of donepezil hydrochloride once daily.
Conditions named in the indications of donepezil and memantine's FDA labels, with every medicine labeled for each:
FDA pharmacologic class: Cholinesterase Inhibitor and N-methyl-D-aspartate Receptor Antagonist.
Source: FDA drug label (Memantine and Donepezil Hydrochlorides Extended-release), Amneal Pharmaceuticals NY LLC, effective December 17, 2024 (SPL set 2335950c-be3b-4248-ad04-e9763aee47d2), via openFDA; the full label on DailyMed
Is there a generic for donepezil and memantine (Namzaric)?
The FDA approved the first generic donepezil and memantine on January 27, 2017. 4 generic applications are approved; 4 of them carry a current (not discontinued) marketing status in Drugs@FDA; that status is not evidence that the generic is on sale.
FDA's NDC Directory lists donepezil and memantine from 5 labelers under a generic (ANDA) application and from 1 brand labeler. A listing means the company has registered the product for sale; it does not show that every pharmacy stocks it.
The Orange Book lists 2 patents for Namzaric capsules, the last expiring on December 5, 2029. A patent or exclusivity date is not the date a generic goes on sale: court cases and settlements move it either way.
- 2014 earliest approval on file
- 2017 first generic approved
- 2029 last listed patent
- red ticks recalls
Source: Drugs@FDA, FDA NDC Directory and the Orange Book (openFDA bulk files, October 8, 2026)
What do pharmacies pay for donepezil and memantine (Namzaric)?
In CMS's NADAC survey of October 7, 2026, pharmacies paid $8.44 per unit (Memantine-donepezil ER 28-10 mg), down 51% from $17.22 on October 8, 2025. The survey records the price, not the reason for a change; large moves often follow a new generic or a list-price change. The chart's scale runs from the lowest to the highest price shown, not from zero. NADAC is what retail pharmacies paid their wholesalers, per unit, in CMS's monthly survey; what a patient pays depends on insurance and the pharmacy.
- Memantine-donepezil ER 14-10 mg (generic)
- Namzaric 28 mg-10 mg capsule (brand)
| Strength and form | Brand or generic | Pharmacy cost | 30 tablets, or one pen or vial | 12-month change |
|---|---|---|---|---|
| Memantine-donepezil ER 14-10 mg | Generic | $6.49 per unit | n/a | -59% |
| Memantine-donepezil ER 28-10 mg | Generic | $8.44 per unit | n/a | -51% |
| Namzaric 14 mg-10 mg capsule | Brand | $19.85 per capsule | $595.43 | +0.2% |
| Namzaric 21 mg-10 mg capsule | Brand | $19.96 per capsule | $598.72 | +0.7% |
| Namzaric 28 mg-10 mg capsule | Brand | $19.80 per capsule | $594.13 | no change |
| Namzaric 7 mg-10 mg capsule | Brand | $19.83 per capsule | $594.80 | +0.1% |
Source: CMS National Average Drug Acquisition Cost (NADAC) survey, October 7, 2026: what retail pharmacies paid per unit; not a counter price
Is donepezil and memantine in shortage?
No donepezil and memantine presentation is listed as in shortage in the FDA Drug Shortage Database (read October 8, 2026); its 2 records are all marked to be discontinued, the latest updated June 15, 2026. ASHP keeps a separate shortage list, which can differ.
| Presentation | Company | Status | Updated |
|---|---|---|---|
| Donepezil Hydrochloride; Memantine Hydrochloride, Capsule, Extended Release, 10 mg; 14 mg (NDC 69238-1248-3) | Amneal Pharmaceuticals | To Be Discontinued | June 15, 2026 |
| Donepezil Hydrochloride; Memantine Hydrochloride, Capsule, Extended Release, 10 mg; 28 mg (NDC 69238-1247-3) | Amneal Pharmaceuticals | To Be Discontinued | June 15, 2026 |
Every donepezil and memantine presentation in the FDA shortage database
Source: FDA Drug Shortage Database via openFDA, updated October 8, 2026
Has donepezil and memantine been recalled?
The FDA's Enforcement Report lists 1 recall naming donepezil and memantine since 2021: 0 Class I (the most serious), 1 Class II, 0 Class III; 0 still ongoing. A recall names products and lots, not every product of the medicine.
| Started | Class | Company | Reason |
|---|---|---|---|
| March 15, 2021 | Class II | Cardinal Health Inc. | CGMP Deviations: Intermittent exposure to temperature excursion during storage. |
Source: FDA Enforcement Report (drug recalls) via openFDA, through October 8, 2026
What does the donepezil and memantine label say about other medicines?
The donepezil and memantine label names 13 other medicines in its interaction, contraindication or warning sections. The sentences are the labels' own; a label lists what its studies and reports found, not every interaction.
| Medicine named | Section | What the label says |
|---|---|---|
| Amantadine | drug interactions | Memantine with Other N-methyl-D-aspartate (NMDA) Antagonists The combined use of memantine hydrochloride with other NMDA antagonists (amantadine, ketamine, and dextromethorphan) has not been systematically evaluated and such use should be approached with caution. |
| Bethanechol | drug interactions | Donepezil with Cholinomimetics and Other Cholinesterase Inhibitors A synergistic effect may be expected when cholinesterase inhibitors, including donepezil hydrochloride, are given concurrently with succinylcholine, similar neuromuscular blocking agents, or cholinergic agonists such as bethanechol. |
| Carbamazepine | drug interactions | Inducers of CYP3A4 (e.g., phenytoin, carbamazepine, dexamethasone, rifampin, and phenobarbital) could increase the rate of elimination of donepezil. |
| Dexamethasone | drug interactions | Inducers of CYP3A4 (e.g., phenytoin, carbamazepine, dexamethasone, rifampin, and phenobarbital) could increase the rate of elimination of donepezil. |
| Dextromethorphan | drug interactions | Memantine with Other N-methyl-D-aspartate (NMDA) Antagonists The combined use of memantine hydrochloride with other NMDA antagonists (amantadine, ketamine, and dextromethorphan) has not been systematically evaluated and such use should be approached with caution. |
| Ketamine | drug interactions | Memantine with Other N-methyl-D-aspartate (NMDA) Antagonists The combined use of memantine hydrochloride with other NMDA antagonists (amantadine, ketamine, and dextromethorphan) has not been systematically evaluated and such use should be approached with caution. |
| Ketoconazole | drug interactions | Drugs on the Metabolism of Donepezil Inhibitors of CYP3A4 (e.g., ketoconazole) and CYP2D6 (e.g., quinidine), inhibit donepezil metabolism in vitro. |
| Phenobarbital | drug interactions | Inducers of CYP3A4 (e.g., phenytoin, carbamazepine, dexamethasone, rifampin, and phenobarbital) could increase the rate of elimination of donepezil. |
| Phenytoin | drug interactions | Inducers of CYP3A4 (e.g., phenytoin, carbamazepine, dexamethasone, rifampin, and phenobarbital) could increase the rate of elimination of donepezil. |
| Quinidine | drug interactions | Drugs on the Metabolism of Donepezil Inhibitors of CYP3A4 (e.g., ketoconazole) and CYP2D6 (e.g., quinidine), inhibit donepezil metabolism in vitro. |
| Rifampin | drug interactions | Inducers of CYP3A4 (e.g., phenytoin, carbamazepine, dexamethasone, rifampin, and phenobarbital) could increase the rate of elimination of donepezil. |
| Sodium bicarbonate | drug interactions | Urine pH is altered by diet, drugs (e.g., carbonic anhydrase inhibitors, sodium bicarbonate) and clinical state of the patient (e.g., renal tubular acidosis or severe infections of the urinary tract). |
| Succinylcholine | drug interactions | DRUG INTERACTIONS Combined use with NMDA antagonists: use with caution. (7.2) Memantine and donepezil hydrochlorides extended-release may interfere with anticholinergic medications. (7.4) Concomitant administration of succinylcholine, similar neuromuscular blocking agents, or cholinergic agonists may lead to … |
Source: FDA drug label (Memantine and Donepezil Hydrochlorides Extended-release), Amneal Pharmaceuticals NY LLC, effective December 17, 2024 (SPL set 2335950c-be3b-4248-ad04-e9763aee47d2), via openFDA; the full label on DailyMed
What do FAERS reports show for donepezil and memantine?
The FDA Adverse Event Reporting System holds 608 reports that list donepezil and memantine among the medicines taken, through July 30, 2026, each a report of something that happened, not proof the medicine caused it; 72 are coded as a death and 117 as a hospital stay. Counts follow how widely a medicine is used and watched, and they are not a measure of how risky it is.
Reports received each year
The most reported reactions
Source: FDA Adverse Event Reporting System (FAERS) via openFDA, reports through July 30, 2026
What else is labeled for the same conditions as donepezil and memantine?
2 other medicines are given the same way (oral) and in the same FDA class as donepezil and memantine or labeled mainly for the same use (alzheimer's disease), the same class first. Alzheimer's disease lists all 7 medicines labeled for it, by any route. They are listed as records, not as substitutes: whether one can replace another is a prescriber's decision.
| Medicine | Shared indication | Generic labelers (oral) | Pharmacy cost | Shortage |
|---|---|---|---|---|
| Rivastigmine | Alzheimer's disease | 11 labelers | $0.164 per capsule 1.5 mg capsule | A presentation being discontinued |
| Galantamine | Alzheimer's disease | 9 labelers | $0.294 per tablet 4 mg tablet | No current entry |
Source: FDA drug labels (indications), NDC Directory, NADAC of October 7, 2026, FDA shortages (October 8, 2026)
What next?
- Other cholinesterase inhibitors
- the pharmacologic class, with prices and generics
- Donepezil and memantine side effects
- the label's list beside FAERS reports
- Donepezil and memantine shortage record
- every presentation, company and date
- Check an interaction
- what two or more labels say about each other